Sarda Proteins board approved a massive hike in authorized capital to ₹100 crore from ₹13 crore. This comes alongside significant management changes, including the resignation of its MD and three directors, and new appointments.
Sarda Proteins Boosts Authorized Capital to ₹100 Crore, Appoints New Leadership
Authorized capital increased from ₹13 crore to ₹100 crore.
New MD and CFO appointed; 3 directors resign.
Reader Takeaway: Capital expansion signals future growth, but leadership changes introduce uncertainty.
What just happened
Sarda Proteins Ltd. has announced a significant increase in its authorized equity share capital, raising it from ₹13 crore to ₹100 crore. This decision was approved by the company's board.
Alongside this financial restructuring, the company has seen a substantial shift in its leadership. The Managing Director, Chirag Shantilal Thumar, along with three directors—Bipinkumar Babubhai Savalia, Khilan Hareshbhai Savaliya, and Chintan Umeshbhai Bhatt—have resigned from their positions. The board has appointed Shirish Dhirajlal Savaliya as the new Managing Director and Drashti Harshadbhai Delvadiya as the new Chief Financial Officer (CFO).
Furthermore, Yagnik Arvindbhai Satasiya, the former CFO, has been redesignated as an Additional Director and Chairperson of the company.
Why this matters
The substantial increase in authorized capital can be a precursor to future fundraising, expansion plans, or bonus share issues, potentially benefiting shareholders if executed effectively. However, the simultaneous high turnover in key personnel, including the MD and multiple directors, introduces a period of uncertainty. Investors will be keen to understand the strategic direction and operational stability under the new leadership.
The backstory
While the filing provides details of the current changes, the previous authorized capital stood at ₹13 crore, with a face value of ₹10 per equity share. The resignations and appointments occurred on July 4, 2026.
What changes now
The company now has a significantly larger authorized capital base, providing flexibility for future financial maneuvers. The leadership structure has been completely revamped with new key appointments. Shareholders will be looking for clear communication from the new management regarding their vision and plans for the company.
Risks to watch
The primary risk is the high turnover of key management and board members. Such frequent changes can lead to strategic drift, operational disruptions, and potential governance concerns until the new team establishes stability and a clear path forward.
Peer comparison
Data for peer comparison on capital structure and management changes is not available in the provided filing text.
Context metrics (time-bound)
- Authorized Capital: Increased from ₹13 crore to ₹100 crore.
- Date of Management/Board Changes: July 4, 2026.
What to track next
Investors should closely monitor future announcements from Sarda Proteins regarding the specific utilization of the increased authorized capital, the strategic plans of the new management team, and any signs of stability in operations and governance.